| Compton Nathaniel Paul, APRN | |
|
2031 Canyon Creek Dr, Aurora, IL 60503-4934 | |
| (630) 544-1244 | |
| Not Available |
| Full Name | Compton Nathaniel Paul |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 2031 Canyon Creek Dr, Aurora, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063179141 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP2300X | Nurse Practitioner - Primary Care | 209024355 (Illinois) | Primary |
| 163W00000X | Registered Nurse | 041414847 (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Loyola University Medical Center | Maywood, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Loyola University Medical Center | 3779488903 | 863 |
News Archive
For more than three decades a new drug for the treatment of breast cancer had not been presented. A group of researchers were given the task of analyzing a marine sponge called Halichondrin okadai and obtained a mesylate eribulin substance that had already been applied to patients with this disease in the stage of metastasis, ie, when the disease spreads to other body parts and the result was that it inhibited tumor growth.
Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.
Researchers from North Carolina State University have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli.
A World Health Organization/United Nations/March of Dimes report ranks countries on their premature birth rates.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
› Verified 1 days ago
| Entity Name | Loyola University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336159961 PECOS PAC ID: 3779488903 Enrollment ID: O20031202000027 |
News Archive
For more than three decades a new drug for the treatment of breast cancer had not been presented. A group of researchers were given the task of analyzing a marine sponge called Halichondrin okadai and obtained a mesylate eribulin substance that had already been applied to patients with this disease in the stage of metastasis, ie, when the disease spreads to other body parts and the result was that it inhibited tumor growth.
Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.
Researchers from North Carolina State University have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli.
A World Health Organization/United Nations/March of Dimes report ranks countries on their premature birth rates.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
› Verified 1 days ago
| Entity Name | Paragon Clinical Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114139946 PECOS PAC ID: 7214034925 Enrollment ID: O20070515000051 |
News Archive
For more than three decades a new drug for the treatment of breast cancer had not been presented. A group of researchers were given the task of analyzing a marine sponge called Halichondrin okadai and obtained a mesylate eribulin substance that had already been applied to patients with this disease in the stage of metastasis, ie, when the disease spreads to other body parts and the result was that it inhibited tumor growth.
Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.
Researchers from North Carolina State University have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli.
A World Health Organization/United Nations/March of Dimes report ranks countries on their premature birth rates.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Compton Nathaniel Paul, APRN 2160 S 1st Ave, Maywood, IL 60153-3328 Ph: (708) 216-9000 | Compton Nathaniel Paul, APRN 2031 Canyon Creek Dr, Aurora, IL 60503-4934 Ph: (630) 544-1244 |
News Archive
For more than three decades a new drug for the treatment of breast cancer had not been presented. A group of researchers were given the task of analyzing a marine sponge called Halichondrin okadai and obtained a mesylate eribulin substance that had already been applied to patients with this disease in the stage of metastasis, ie, when the disease spreads to other body parts and the result was that it inhibited tumor growth.
Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.
Researchers from North Carolina State University have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli.
A World Health Organization/United Nations/March of Dimes report ranks countries on their premature birth rates.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
› Verified 1 days ago
Courtney Harley, ANP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2720 E New York St, Ste 108, Aurora, IL 60502 Phone: 630-820-7045 Fax: 630-820-7047 | |
Tochi Okwueze, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 400 N Highland Ave, Aurora, IL 60506 Phone: 630-978-2532 | |
Heidijo Elyea, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1256 Waterford Drive, Suite 120, Aurora, IL 60504 Phone: 630-499-6688 Fax: 630-499-6689 | |
Mrs. Haley S.v. Murphy, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 400 N Highland Ave, Aurora, IL 60506 Phone: 630-892-4355 | |
Ms. Carole Wolfson, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 581 Sullivan Rd Ste B, Aurora, IL 60506 Phone: 630-859-3877 Fax: 630-859-8920 | |
Ms. Kenisha Francisco, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 400 N Highland Ave, Aurora, IL 60506 Phone: 630-978-2532 | |
Terra L Kolacki, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 444 N Eola Rd Ste 110, Aurora, IL 60502 Phone: 630-692-5660 Fax: 630-692-5661 |